FLJ21986 Inhibitors
FLJ21986 inhibitors encompass a diverse range of compounds thatinterrupt the signaling cascades and cellular processes that FLJ21986 is involved in, ultimately leading to its decreased functional activity. For example, PD 98059 and U0126 are both inhibitors of MEK, a kinase that lies upstream of ERK in the MAPK pathway. FLJ21986, being a protein that is regulated by the MAPK pathway, would have its activity diminished when MEK is inhibited, resulting in the suppression of downstream signaling events that depend on FLJ21986. Similarly, LY294002 and Wortmannin exert their inhibitory effects by targeting PI3K, which is critical for the PI3K/AKT/mTOR signaling axis. As FLJ21986 is postulated to be a downstream effector in this pathway, the inhibition of PI3K would lead to a cascade of events culminating in the reduced activity of FLJ21986 due to the diminished phosphorylation and activation of AKT and subsequent downregulation of mTOR activity.
In parallel, other inhibitors such as Rapamycin, Triciribine, and Gefitinib disrupt the activity of FLJ21986 through their action on specific proteins that modulate the functional state of FLJ21986 indirectly. Rapamycin binds to and inhibits mTOR, a master regulator of cell growth and metabolism, which would impact FLJ21986 if it is involved in mTOR-mediated processes. Triciribine targets the AKT kinase pathway, downstream of PI3K, and a reduction in AKT activity would lead to a decrease in FLJ21986 activity if it is AKT-dependent. Gefitinib, by blocking EGFR tyrosine kinase, would attenuate the downstream signaling involving FLJ21986 if it is a component of the EGFR signaling network. Other compounds like Y-27632, SB203580, SP600125, PP2, and ZM 336372 target various kinases and enzymes like ROCK, p38 MAP kinase, JNK, Src family kinases, and Raf kinases respectively, each affecting different aspects of cellular function. By inhibiting these kinases, the compounds indirectly reduce the functionality of FLJ21986, assuming it plays a role in the pathways regulated by these enzymes. Collectively, these inhibitors underscore a strategic approach to attenuate the signaling pathways and biological processes that are crucial for FLJ21986's activity, leading to its functional inhibition without affecting the general pathways or the transcription and translation of the protein itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective and potent inhibitor of MAPK/ERK kinase (MEK), which acts upstream of ERK in the MAPK pathway. FLJ21986 is indirectly inhibited as the MAPK pathway is crucial for various cellular responses including proliferation and differentiation; inhibition of MEK leads to reduced ERK activation resulting in decreased activity of downstream proteins like FLJ21986. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which is a part of the PI3K/AKT/mTOR pathway. The inhibition of PI3K can result in reduced phosphorylation and activation of AKT, leading to a decrease in mTOR activity. As FLJ21986 is involved in downstream signaling of this pathway, its activity is diminished when PI3K is inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin), which is a central protein in regulating cell growth and metabolism. By inhibiting mTOR, rapamycin can indirectly reduce the functional activity of FLJ21986 if FLJ21986 is a downstream effector in the mTOR signaling pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of Rho-associated protein kinase (ROCK), which plays a significant role in regulating cell shape, attachment, and motility. By inhibiting ROCK, Y-27632 can lead to changes in the cytoskeleton that could impact the localization or activity of FLJ21986, assuming FLJ21986 is involved in these cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which participates in the response to stress and inflammatory cytokines. Inhibition of p38 can affect the cellular stress response and potentially decrease the functional activity of FLJ21986 if it is implicated in the stress response pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the control of cell fate decisions. If FLJ21986 functions downstream of or in conjunction with JNK signaling, inhibition of JNK by SP600125 would result in reduced activity of FLJ21986. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which inhibits the MAPK/ERK pathway similarly to PD 98059. By blocking MEK1/2, U0126 diminishes ERK signaling, thereby potentially inhibiting the function of FLJ21986 if it is associated with the ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, acting similarly to LY294002. It blocks the PI3K/AKT pathway, leading to downregulation of downstream signaling pathways and potentially inhibiting the activity of FLJ21986 if it is involved in this pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the AKT pathway, which might result in reduced activation of downstream proteins such as FLJ21986, assuming its activity is AKT-dependent. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which are involved in various signaling pathways related to cell growth and survival. Inhibition of Src kinases by PP2 could lead to an indirect decrease in FLJ21986 activity if FLJ21986 is part of Src kinase-mediated signaling. | ||||||